Jonah Feldman

The current landscape for T-cell acute lymphoblastic leukemia has been influenced by 2 key phase 3 trials, Children’s Oncology Group AALL0434 and AALL1231.

During an interview with Targeted Oncology, Matthew A. Powell, MD, discussed the significance of the FDA approval and his presentation of the results from the RUBY trial.

A retrospective study of the CATCH-IT database provided data on patients with HIV who received immunotherapy for multiple cancer types, demonstrating safety and efficacy in most cases.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

Results from the CARTITUDE-2 trial of cilta-cel for multiple myeloma support the use of chimeric antigen receptor T-cell therapy earlier in therapy than what is currently approved.

During an interview with Targeted Oncology, Lindsey S. Treviño, PhD, discussed how racial and socioeconomic disparities impact access to CAR T-cell therapy, clinical trials, and more.

In an interview with Targeted Oncology, Yael C. Cohen, MD, senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, discussed the results from RedirecTT-1 she presented at ASCO 2023.

A trial of targeted treatment with improved drug delivery to the brain met its primary end point for overall survival in patients with recurrent glioblastoma.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

Results from 2 trials of lisocabtagene maraleucel presented at ICML 2023 demonstrated efficacy and tolerability in patients with follicular lymphoma and mantle cell lymphoma.

Though the radioligand therapy lutetium Lu 177 vipivotide tetraxetan was approved in 2022 for PSMA-avid patients, several practical considerations have limited its use among patients with prostate cancer.

Patients aged 80 years or older and/or considered frail who received acalabrutinib for chronic lymphocytic leukemia experienced toxicities consistent with prior trials.

In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.

When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.

A comprehensive analysis of the phase 1 LEGEND-2 study shows a correlation between cytokine release syndrome and coagulation disorders inpatient with multiple myeloma treated with CAR T cells.

An analysis of Medicare patients with follicular lymphoma revealed which characteristics correlated with overall survival.

Findings from a survey found that many physicians used new strategies to manage their patients during the COVID-19 pandemic, some of which, such as the use of telehealth, are expected to continue into the future.

In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.

It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

In an interview with Targeted Oncology for Melanoma Monday, Meredith McKean, MD, MPH, discussed recent and upcoming advances in melanoma treatment.

A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.

Studies have increasingly supported the use of total neoadjuvant therapy, moving chemotherapy use ahead of surgical resection of rectal tumors.

In an interview with Targeted Oncology for Esophageal Cancer Awareness Month, Arturo Loaiza-Bonilla, MD, MSEd, discussed the pressing need to keep up with the developments in targeted therapies for esophageal and GEJ cancers.

The addition of eftilagimod alpha to pembrolizumab in patients with PD-1 resistant non–small cell lung cancer led to tumor shrinkage.

The rise of earlier-onset disease and the introduction of noninvasive testing has changed the landscape of colorectal cancers for oncologists.

The FDA released a draft guidance for drug sponsors of clinical trials in oncology, outlining its move toward requiring randomized controlled trials to grant accelerated approvals for most oncology therapeutics.

A patient who received AB8939, a microtubule inhibitor, in a phase 1 study, had a significant reduction in bone marrow blasts, showing its potential to treat drug-resistant acute myeloid leukemia.

A study of isatuximab and cemiplimab in 3 lymphoma subtypes will not continue, for reasons unrelated to safety.

Investigators from the China ARCHES trial of enzalutamide plus androgen deprivation therapy announced that it had met its primary end point in Chinese patients with metastatic hormone-sensitive prostate cancer.